ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $825,793,457 | -20.7% | 30,427,172 | -10.2% | 0.07% | -18.4% |
Q2 2023 | $1,041,601,849 | -63.8% | 33,884,250 | -57.6% | 0.09% | -34.1% |
Q1 2023 | $2,881,255,400 | +65.3% | 79,968,232 | +81.3% | 0.13% | -23.7% |
Q4 2022 | $1,743,241,625 | +1.0% | 44,110,365 | +2.7% | 0.17% | -3.9% |
Q3 2022 | $1,726,046,000 | +14.2% | 42,957,880 | +19.5% | 0.18% | +19.2% |
Q2 2022 | $1,511,480,000 | +37.5% | 35,953,354 | +27.5% | 0.15% | +71.6% |
Q1 2022 | $1,098,872,000 | +24.9% | 28,205,161 | +27.7% | 0.09% | +35.4% |
Q4 2021 | $879,880,000 | +27.4% | 22,079,795 | +15.5% | 0.06% | +18.2% |
Q3 2021 | $690,627,000 | -30.1% | 19,109,757 | -20.7% | 0.06% | -28.6% |
Q2 2021 | $987,693,000 | -19.0% | 24,095,929 | -13.8% | 0.08% | -26.0% |
Q1 2021 | $1,219,302,000 | -2.3% | 27,952,820 | +12.1% | 0.10% | -6.3% |
Q4 2020 | $1,248,374,000 | +65.6% | 24,942,548 | +37.1% | 0.11% | +46.1% |
Q3 2020 | $753,864,000 | +1.4% | 18,188,304 | +11.2% | 0.08% | -7.3% |
Q2 2020 | $743,419,000 | – | 16,356,491 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
Brown University | 381,759 | $16,652,000 | 11.44% |
Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |